AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8422279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin or carboplatin and cyclophosphamide with or without doxorubicin for six courses after primary surgery
Number of subjects: 226
Study 3668980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold provocation (cold challenges)
Number of subjects: 25
Study 29306047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral strategy for discontinuing long-term serotonin reuptake inhibitors (SRIs)
Number of subjects: 0
Study 29306047 — intervention group
Group type: COMPARATOR
Intervention: Enhanced control condition
Number of subjects: 0
Study 27169630 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief smoking cessation (SC) advice using the AWARD model, active referral to SC services plus a referral card and a health warning leaflet (active referral group)
Number of subjects: 1291
Study 27169630 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief SC advice using AWARD model and health warning leaflet (brief advice group)
Number of subjects: 1291
Study 27169630 — intervention group
Group type: COMPARATOR
Intervention: General very brief advice with a self-help booklet (control group)
Number of subjects: 1291
Study 24642779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy dessert containing maltitol and scFOS (35g dosage)
Number of subjects: 36
Study 24642779 — intervention group
Group type: COMPARATOR
Intervention: Control dessert containing dextrose
Number of subjects: 36
Study 23084678 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-point, full-sized mesh method
Number of subjects: 87
Study 23084678 — intervention group
Group type: COMPARATOR
Intervention: 2-point, half-sized mesh method
Number of subjects: 87
Study 21073697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 1334
Study 21073697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1334
Study 18720469 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse coloplasty pouch (TCP)
Number of subjects: 149
Study 18720469 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon J pouch (CJP)
Number of subjects: 149
Study 18720469 — intervention group
Group type: COMPARATOR
Intervention: Both groups (TCP and CJP)
Number of subjects: 149
Study 16012278 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d) + Cognitive Behavioral Therapy (12 sessions)
Number of subjects: 160
Study 16012278 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d) + Motivational Enhancement Therapy (4 sessions)
Number of subjects: 160
Study 16012278 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Cognitive Behavioral Therapy (12 sessions)
Number of subjects: 160
Study 16012278 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Motivational Enhancement Therapy (4 sessions)
Number of subjects: 160
Study 14964345 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacteol group (2 capsules of Lacteol Fort twice a day for 4 weeks)
Number of subjects: 137
Study 14964345 — intervention group
Group type: COMPARATOR
Intervention: Lacidophilin group (5 chewable tablets of Lacidophilin three times a day for 4 weeks)
Number of subjects: 137
Study 14964345 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacteol group
Number of subjects: 137
Study 10568184 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelialized grafts (27 grafts in phase 1)
Number of subjects: 100
Study 10568184 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelialized grafts (86 grafts in phase 2)
Number of subjects: 100
Study 10568184 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 untreated grafts in phase 1)
Number of subjects: 100
Study 8759812 — intervention group
Group type: EXPERIMENTAL
Intervention: zofenopril (7.5 to 30 mg twice daily)
Number of subjects: 1146
Study 8759812 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1146
Study 1816661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried unripe fruit powder of 'bel' (Aegle marmelos)
Number of subjects: 82
Study 1816661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried powdered plant of 'thankuni' (Hydrocotyle asiatica)
Number of subjects: 82
Study 1816661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried powdered plant of 'gandhavadulia' (Paederia foetida)
Number of subjects: 82
Study 1816661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 82
Study 1816661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 7065839 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of dextroamphetamine (intravenous)
Number of subjects: 0
Study 7065839 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind pimozide treatment
Number of subjects: 0
Study 7065839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine administration
Number of subjects: 0
Study 7065839 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 0
Study 7065839 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepimozide psychosis ratings
Number of subjects: 0
Study 31358046 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-fragmented adipose tissue injection (Lipogems®)
Number of subjects: 114
Study 31358046 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 114
Study 29912357 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocarbon at 0.5% of substrate DM
Number of subjects: 16
Study 29912357 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocarbon at 1% of substrate DM
Number of subjects: 16
Study 29912357 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocarbon at 2% of substrate DM
Number of subjects: 16
Study 29912357 — intervention group
Group type: COMPARATOR
Intervention: Control (0% biocarbon)
Number of subjects: 16
Study 27176822 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine during pregnancy
Number of subjects: 346
Study 24798113 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac suppository
Number of subjects: 90
Study 24798113 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository
Number of subjects: 90
Study 24798113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22469659 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education
Number of subjects: 0
Study 22469659 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face education
Number of subjects: 0
Study 19744462 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemihepatectomy preserving ventral RAS
Number of subjects: 30
Study 17283264 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 5804
Study 17283264 — intervention group
Group type: EXPERIMENTAL
Intervention: Top third CRP levels
Number of subjects: 5804
Study 17283264 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted CRP levels
Number of subjects: 5804
Study 17283264 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP
Number of subjects: 5804
Study 15197541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 2.5 mg daily
Number of subjects: 474
Study 15197541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 20 mg intermittently
Number of subjects: 474
Study 15197541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 1.0 mg IV every 3 months
Number of subjects: 474
Study 15197541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 0.5 mg IV every 3 months
Number of subjects: 474
Study 15197541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study 11892374 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 34000
Study 11892374 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 34000
Study 9841833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ia-TT conjugate (dose range, 3.75-63 microg of CPS component)
Number of subjects: 190
Study 9841833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ib-TT conjugate (dose range, 3.75-63 microg of CPS component)
Number of subjects: 190
Study 9841833 — intervention group
Group type: COMPARATOR
Intervention: Uncoupled Ia CPS
Number of subjects: 190
Study 9841833 — intervention group
Group type: COMPARATOR
Intervention: Uncoupled Ib CPS
Number of subjects: 190
Study 9841833 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 190
Study 8749599 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing ethinylestradiol and levonorgestrel
Number of subjects: 31
Study 8749599 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing ethinylestradiol and desogestrel
Number of subjects: 31
Study 8749599 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 2031076 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 micrograms of cyclopenthiazide
Number of subjects: 73
Study 2031076 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of cyclopenthiazide
Number of subjects: 73
Study 2031076 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during 8-week run-in period)
Number of subjects: 73
Study 6124805 — intervention group
Group type: EXPERIMENTAL
Intervention: Early phototherapy started at serum bilirubin 250 mumol/l
Number of subjects: 40
Study 6124805 — intervention group
Group type: COMPARATOR
Intervention: Late phototherapy started at serum bilirubin 320 mumol/l
Number of subjects: 40
Study 6124805 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 40
Study 29736552 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left inferior frontal gyrus (l-IFG)
Number of subjects: 13
Study 29736552 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left posterior superior temporal gyrus (l-STG)
Number of subjects: 13
Study 29736552 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS/pseudo-stimulation
Number of subjects: 13
Study 27419128 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser with Clearfil s3 Bond Plus
Number of subjects: 72
Study 27419128 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser with Xeno® Select
Number of subjects: 72
Study 27419128 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser with Futurabond U
Number of subjects: 72
Study 27419128 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond bur with Clearfil s3 Bond Plus
Number of subjects: 72
Study 27419128 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond bur with Xeno® Select
Number of subjects: 72
Study 27419128 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond bur with Futurabond U
Number of subjects: 72
Study 27419128 — intervention group
Group type: COMPARATOR
Intervention: Comparison of enamel with cervical walls
Number of subjects: 72
Study 25617202 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collection of HPV DNA offered by community health workers during home visits
Number of subjects: 7650
Study 25617202 — intervention group
Group type: COMPARATOR
Intervention: Standard advice to attend a health clinic for cervical screening
Number of subjects: 7650
Study 23696855 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum beta-hCG levels on day 7 after medical abortion
Number of subjects: 2843
Study 23696855 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum beta-hCG levels on day 14 after medical abortion
Number of subjects: 2843
Study 23696855 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Ang-2 levels on day 7 after medical abortion
Number of subjects: 2843
Study 23696855 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Ang-2 levels on day 14 after medical abortion
Number of subjects: 2843
Study 23696855 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between Ang-2 and beta-hCG levels
Number of subjects: 2843
Study 20578849 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate orthodontic loading (11 implants)
Number of subjects: 13
Study 20578849 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 implants)
Number of subjects: 13
Study 18197267 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 203
Study 16798470 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐DTPA aerosol scintigraphy
Number of subjects: 25
Study 16798470 — intervention group
Group type: COMPARATOR
Intervention: DLCO
Number of subjects: 25
Study 12702108 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser + SRP (test)
Number of subjects: 20
Study 12702108 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser alone (control)
Number of subjects: 20
Study 10994565 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 500
Study 10994565 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 500
Study 10994565 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin (surgical room)
Number of subjects: 500
Study 10994565 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (surgical room)
Number of subjects: 500
Study 10994565 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin (medical ward)
Number of subjects: 500
Study 10994565 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (medical ward)
Number of subjects: 500
Study 10994565 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin (VR patients, surgical room)
Number of subjects: 500
Study 10994565 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (VR patients, surgical room)
Number of subjects: 500
Study 10994565 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin (VR patients, medical ward)
Number of subjects: 500
Study 10994565 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (VR patients, medical ward)
Number of subjects: 500
Study 9078827 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta (n = 15)
Number of subjects: 27
Study 9078827 — intervention group
Group type: COMPARATOR
Intervention: Exosurf (n = 12)
Number of subjects: 27
Study 7943919 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine hydrochloride with 1:200,000 epinephrine (Ultracain DS)
Number of subjects: 20
Study 7943919 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with 1:80,000 epinephrine (Xylocain‐Adrenalin)
Number of subjects: 20
Study 3082677 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin vasodilator cream
Number of subjects: 0
Study 3082677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29314645 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 216
Study 29314645 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 216
Study 29314645 — intervention group
Group type: COMPARATOR
Intervention: Placebo→tofacitinib 5 mg twice daily
Number of subjects: 216
Study 29314645 — intervention group
Group type: COMPARATOR
Intervention: Placebo→tofacitinib 10 mg twice daily
Number of subjects: 216
Study 27340919 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2933
Study 27340919 — intervention group
Group type: COMPARATOR
Intervention: Vasodilators and diuretics
Number of subjects: 2933
Study 23792149 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg loading dose followed by 40 mg every 2 weeks)
Number of subjects: 43
Study 23792149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 23064592 — intervention group
Group type: EXPERIMENTAL
Intervention: model-based magnetization transfer (mMT) imaging
Number of subjects: 54
Study 23064592 — intervention group
Group type: COMPARATOR
Intervention: magnetization transfer ratio (MTR)
Number of subjects: 54
Study 20629134 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (6-month minimally supervised); attended a monthly exercise class and exercised at home three times weekly
Number of subjects: 48
Study 20629134 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 48
Study 20629134 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 18373988 — intervention group
Group type: EXPERIMENTAL
Intervention: MP+SS (massed practice training combined with somatosensory stimulation)
Number of subjects: 24
Study 18373988 — intervention group
Group type: EXPERIMENTAL
Intervention: SS (somatosensory stimulation only)
Number of subjects: 24
Study 18373988 — intervention group
Group type: EXPERIMENTAL
Intervention: MP (massed practice training only)
Number of subjects: 24
Study 18373988 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 24
Study 16093518 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic growth (PTG) reported by adolescents and their parents
Number of subjects: 150
Study 16093518 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived treatment severity and life threat
Number of subjects: 150
Study 16093518 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic stress symptoms (PTSS)
Number of subjects: 150
Study 16093518 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis after age 5
Number of subjects: 150
Study 12658206 — intervention group
Group type: EXPERIMENTAL
Intervention: Active amiodarone
Number of subjects: 82
Study 12658206 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued amiodarone
Number of subjects: 82
Study 12658206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 12658206 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (both active and discontinued)
Number of subjects: 82
Study 10678690 — intervention group
Group type: EXPERIMENTAL
Intervention: Invariable, neutral distractors
Number of subjects: 0
Study 10678690 — intervention group
Group type: COMPARATOR
Intervention: Variable, task-relevant distractors
Number of subjects: 0
Study 8777336 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg b.i.d. for 3 months)
Number of subjects: 0
Study 8777336 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg b.i.d. for 6 months)
Number of subjects: 0
Study 8777336 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment period (no intervention)
Number of subjects: 0
Study 1890008 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.075%
Number of subjects: 15
Study 1890008 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 15
Study 4042800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 65
Study 4042800 — intervention group
Group type: COMPARATOR
Intervention: Exercise intervention
Number of subjects: 65
Study 4042800 — intervention group
Group type: COMPARATOR
Intervention: Diet plus exercise intervention
Number of subjects: 65
Study 4042800 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 65
Study 31433809 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 oz. pomegranate juice
Number of subjects: 77
Study 31433809 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 oz. polyphenol-free juice)
Number of subjects: 77
Study 29249596 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling by pharmacist bi-monthly for one year
Number of subjects: 164
Study 29249596 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 164
Study 27421877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia
Number of subjects: 10
Study 27421877 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 10
Study 24633717 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence Support Program (ASP)
Number of subjects: 889
Study 24633717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 889
Study 22401804 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated curcumin (ECB)
Number of subjects: 3
Study 22401804 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated curcumin plus other polyphenols (ECBB)
Number of subjects: 3
Study 22401804 — intervention group
Group type: COMPARATOR
Intervention: Free curcumin (FCB)
Number of subjects: 3
Study 20048680 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-focused intervention (report given to physician before visit with adherence data)
Number of subjects: 156
Study 20048680 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-focused intervention
Number of subjects: 156
Study 20048680 — intervention group
Group type: COMPARATOR
Intervention: Control visits
Number of subjects: 156
Study 17490976 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and riboflavin supplementation (30 mg Fe and 6 mg riboflavin) with vitamin A-fortified rice
Number of subjects: 38
Study 17490976 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (VA only)
Number of subjects: 38
Study 15935958 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrode configuration
Number of subjects: 10
Study 15935958 — intervention group
Group type: COMPARATOR
Intervention: Laplacian electrode configuration
Number of subjects: 10
Study 12925454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab 2.0‐mg/kg bolus
Number of subjects: 960
Study 12925454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab 2.0‐mg/kg bolus and 0.05‐mg/kg per h infusion for 20 hours
Number of subjects: 960
Study 12925454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 960
Study 10813280 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 64
Study 10813280 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 64
Study 9122580 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy (uvulopalatopharyngoplasty (UPPP), nasal surgery, maxillofacial surgery)
Number of subjects: 0
Study 9122580 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 0
Study 1513833 — intervention group
Group type: EXPERIMENTAL
Intervention: Foamed gel dressing
Number of subjects: 0
Study 1513833 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 0
Study 6186852 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of acebutolol
Number of subjects: 26
Study 6186852 — intervention group
Group type: COMPARATOR
Intervention: Twice-a-day dosing of acebutolol
Number of subjects: 26